4D Molecular Therapeutics, Inc. growth

Reported trailing growth, forward expectations and three-year compound growth rates.

Trailing growth

Year over year

Revenue: —
EBITDA: +17.4%
EBIT: +11.7%
EPS: +16.4%
Free cash flow: +17.1%
Operating cash flow: +15.5%

Forward estimates

Revenue: -89.4%
EBITDA: +94.3%
EPS: +34.6%

Three-year CAGR

Revenue: +200.9%
EBITDA: +14.1%
EBIT: +15.1%
Net income: +12.9%
EPS: +18.8%
Free cash flow: +21.2%

Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.